GLP-1 drugs work for weight loss, study finds

I’m a weight-loss doctor—the unusual complication I’m seeing from Ozempic-like drugs
A top NYC weight-loss doctor shared the surprising skin complication that he’s encountered in patients using GLP-1 drugs like Ozempic.
GLP-1 Drugs For Weight Loss Aren’t Cost-Saving Yet
Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.
Preserving muscle with GLP-1 weight loss drugs: Big deal or nothing to worry about?
On the surface, the formula for weight loss seems simple: eat less and move more. But giving that advice to someone with obesity is like telling someone with depression to cheer up. Weight loss isn't easy,
Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey
"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated that almost 50 million adults in employer plans meet the clinical criteria for taking such drugs, which can cost thousands of dollars annually per person," according to a report from Kaiser Family Health (KFF) in October.
How do GLP-1 drugs work for weight loss?
Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame themselves for it.
Some GLP-1s Achieve More Weight Loss Than Others: Study
We found that, of the 12 GLP-1 (drugs) identified by our search, the greatest mean body weight reduction was reported in randomized controlled trials of retatrutide, tirzepatid
Two years on, are GLP-1 drugs such as Ozempic and Mounjaro here to stay?
In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection that promised to transform the lives of those struggling with obesity. The click-baity headlines surrounding Ozempic,
GLP-1 RAs Efficacious for Weight Loss in Overweight, Obesity Without Diabetes
For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published online Jan. 7 in the Annals of Internal Medicine.
Health Matters: GLP-1 drugs work for weight loss, study finds
McGill University researchers say their study has found GLP-1 drugs are safe and effective for treating obesity and overweight adults without diabetes. The authors say the findings support using the medication to treat those who are overweight and obese among otherwise healthy patients.
Hosted on MSN1d
Sugary Drinks Tied to 2M Diabetes Cases; Diagnosing LADA; Top GLP-1 for Weight Loss
Investigational once-weekly retatrutide yielded the greatest weight loss of all GLP-1 receptor agonists, up to 22.1% after 48 ...
As demand for weight-loss drugs rises, states grapple with Medicaid coverage
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...
FierceBiotech1d
Metsera links GLP-1 drug to 11% weight loss after 12 weeks, teeing up trial of monthly dosing
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
Medscape2d
Early Intervention Central to Treating Muscle Mass Loss in Patients Losing Weight With GLP-1 Meds
Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...
Fierce Healthcare22h
Found introducing oral dissolvable GLP-1 tablet at reduced price
Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...
Ozempic and Similar Drugs May Offer Health Benefits Beyond Weight Loss, Including Reduced Alcohol Cravings
Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...
Medscape1d
Retatrutide Produces Greatest Weight Loss
Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...